Sign In
Buy CYCN
$3.00
-0.0200 (-0.662%)
At Close: Jun 03, 2026
Cyclerion Therapeutics, Inc. (CYCN) Is Burning These Hedge Funds
08:43pm, Thursday, 12'th Dec 2019
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P; 500 fell by about 4.8% during 2018 a
Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
12:00pm, Wednesday, 27'th Nov 2019
CAMBRIDGE, Mass., Nov. 27, 2019 -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate.
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View
02:52pm, Friday, 01'st Nov 2019
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut
12:08pm, Thursday, 31'st Oct 2019
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 30.) Allergan plc (NYSE: AGN ) Arrowhead Pha
Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial
12:17pm, Wednesday, 30'th Oct 2019
New biopharma startup Cyclerion Therapeutics has stumbled out of the gate, disclosing Wednesday that one of its lead drug candidates failed in a mid-stage study.
Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
11:31am, Wednesday, 30'th Oct 2019
Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced
Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced
Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced
Read This Before Selling Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares
05:22pm, Wednesday, 25'th Sep 2019
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
12:00pm, Tuesday, 10'th Sep 2019
Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseas
– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study.
Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
02:58pm, Wednesday, 31'st Jul 2019
Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.
What Kind Of Shareholders Own Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)?
07:23pm, Wednesday, 24'th Jul 2019
A look at the shareholders of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) can tell us which group is most powerful...
Merkel’s GREATEST nightmare: How Germany’s ageing population could rip the country apart
10:32am, Tuesday, 31'st Oct 2017
ANGELA MERKEL’S attempts to unite her divided conservative alliance could be further scuppered as Germany’s ageing population threatens to tear the country apart.
SGC, a new spirit in monotone market
02:05pm, Thursday, 23'rd Feb 2017
If ever there was a project for the European Union to abet and strengthen its energy security it’s the Southern Gas Corridor.
